Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

186
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
186
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

174
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
174
Angina IV: Management01:26

Angina IV: Management

190
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
190
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

186
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
186
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

249
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
249
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

274
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
274

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Role of Cardiovascular Disease Journals in Reporting Sex and Gender in Research.

European journal of preventive cardiology·2025
Same author

The Role of Cardiovascular Disease Journals in Reporting Sex and Gender in Research.

European heart journal. Acute cardiovascular care·2025
Same author

The Role of Cardiovascular Disease Journals in Reporting Sex and Gender in Research.

European heart journal·2025
Same author

The Role of Cardiovascular Disease Journals in Reporting Sex and Gender in Research.

Journal of the American College of Cardiology·2025
Same author

Role of Cardiovascular Disease Journals in Reporting Sex and Gender in Research.

Circulation·2025
Same author

The Role of Cardiovascular Disease Journals in Reporting Sex and Gender in Research.

JAMA cardiology·2025

Related Experiment Video

Updated: Dec 28, 2025

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

4.1K

Treatment of coronary microvascular dysfunction.

C Noel Bairey Merz1, Carl J Pepine2, Hiroki Shimokawa3

  • 1Barbra Streisand Women's Heart Center, Smidt Heart Institute, Cedars-Sinai, 127 S. San Vicente Blvd, Suite A3600, Los Angeles, CA 90048, USA.

Cardiovascular Research
|February 23, 2020
PubMed
Summary

Patients with ischaemia and non-obstructive coronary artery disease (INOCA) often have coronary microvascular dysfunction (CMD). Evidence suggests potent statins and ACE inhibitors improve symptoms and function, with ongoing trials to guide treatment.

Keywords:
AnginaCMDIschaemiaWomenINOCA

More Related Videos

Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter
07:53

Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter

Published on: June 16, 2022

3.7K
Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
06:32

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats

Published on: June 28, 2019

8.4K

Related Experiment Videos

Last Updated: Dec 28, 2025

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

4.1K
Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter
07:53

Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter

Published on: June 16, 2022

3.7K
Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
06:32

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats

Published on: June 28, 2019

8.4K

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Pharmacotherapy

Background:

  • Ischaemia and non-obstructive coronary artery disease (INOCA) affects many patients, often presenting with coronary microvascular dysfunction (CMD).
  • Existing guidelines lack evidence-based data for INOCA management, particularly for the large female population affected.
  • Coronary endothelial and microvascular dysfunction are documented, often alongside non-obstructive atherosclerosis.

Purpose of the Study:

  • To review current evidence on pharmacotherapy for coronary microvascular dysfunction (CMD) in patients with INOCA.
  • To highlight the need for evidence-based data to guide treatment strategies for this under-treated population.
  • To discuss ongoing trials and novel treatments for INOCA.

Main Methods:

  • Review of existing literature on pharmacotherapy for CMD.
  • Analysis of findings from pilot studies and ongoing randomized controlled trials (e.g., WARRIOR trial).
  • Examination of evidence supporting invasive diagnostic testing and stratified therapy.

Main Results:

  • Potent statins combined with angiotensin-converting enzyme inhibitors (ACE-I) show promise in improving angina, stress test results, and coronary vascular function.
  • The Coronary Microvascular Angina trial suggests benefits of invasive testing and stratified therapy for symptom relief and quality of life.
  • The WARRIOR trial is evaluating intense medical therapy for longer-term outcomes in INOCA patients.

Conclusions:

  • Intense medical therapy, including statins and ACE-I, appears beneficial for improving symptoms and function in INOCA patients with CMD.
  • Further randomized controlled trials are crucial to establish evidence-based guidelines for managing INOCA.
  • Novel therapeutic approaches are under development and show promise for future treatment strategies.